Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy

Cervera, Ricard; Viñas, Odette; Ramos-Casals, Manuel; Font, Josep; Garcı́a-Carrasco, Mario; Sisó, Antoni; Ramı́rez, Francisco; Machuca, Y; Vives, Jordi; Ingelmo, M; Burlingame, R W

doi:10.1136/ard.62.5.431

Cited by 100 publications

(69 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence has accumulated in recent years that antichromatin autoantibodies are correlated even better with lupus nephritis than anti-dsDNA [10]. In one strain of mouse, antichromatin antibodies are a ubiquitous feature of murine lupus, and are necessary but not sufficient for the development of glomerulonephritis [20,21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Kim

Jeon

Choi

et al. 2008

Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Antinucleosome immunoglobulin G antibodies are a more sensitive marker of SLE than anti-dsDNA, and are almost exclusively found in SLE, scleroderma, and mixed connective tissue diseases [6]. Several studies have been published evaluating the role of antichromatin antibodies in SLE with various results [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Kim

Jeon

Choi

et al. 2008

Clinical Immunology

View full text Add to dashboard Cite

“…Antinucleosome antibodies are reportedly present in 70-100% of patients with SLE, and are fairly sensitive (48-100%) and highly specific (90-99%) for SLE [Cervera et al 2003;Chabre et al 1995;GomezPuerta et al 2008]. Among SLE patients, antinucleosome antibodies are more likely to be detected in patients with nephritis and may serve as a useful biomarker in the diagnosis of active lupus nephritis [Cervera et al 2003;Grootscholten et al 2007;Gutierrez-Adrianzen et al 2006].…”

Section: Antinucleosome Antibodiesmentioning

confidence: 99%

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Liu

Kao

Manzi

et al. 2013

Therapeutic Advances in Musculoskeletal

106

View full text Add to dashboard Cite

Abstract:The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.

show abstract

“…In such a scenario, circulating antinucleosome/histone Abs would only contribute to arthritis if inflammation had been initiated in a joint by other means-a mechanism similar to that proposed for anti-CCP immunity in RA (4) and also a plausible explanation for the absence of arthritis in many persons who have detectable antihistone autoAbs. The notion of anti-nucleosome/histone Abs being arthritogenic is plausible in RA based on detection of such Abs in variable percentages of RA patients in several studies (35,36), and is even more plausible in other diseases featuring inflammatory arthritis (e.g., systemic lupus and oligoarticular juvenile inflammatory arthritis) that are more strongly associated with Abs to nucleosomal components (37,38). Alternatively, because chromatin has the potential of activating cells of the innate and adaptive immune systems by triggering the TLR9 receptor (39), nucleosome-containing material could deliver activating signals to infiltrating cells in the joint as well.…”

Section: Discussionmentioning

confidence: 99%

A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis

Monach

Hueber²,

Kessler³

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Deposits of Ig and complement are abundant in affected joints of patients with rheumatoid arthritis (RA) and in animal models of RA in which antibodies are demonstrably pathogenic. To identify molecular targets of the Igs deposited in arthritic joints, which may activate local inflammation, we used a combination of mass spectrometry (MS) and protein microarrays. Immune complexes were affinity-purified from surgically removed joint tissues of 26 RA and osteoarthritis (OA) patients. Proteins complexed with IgG were identified by proteomic analysis using tandem MS. A striking diversity of components of the extracellular matrix, and some intracellular components, copurified specifically with IgG from RA and OA tissues. A smaller set of autoantigens was observed only in RA eluates. In complementary experiments, IgG fractions purified from joint immune complexes were tested on protein microarrays against a range of candidate autoantigens. These Igs bound a diverse subset of proteins and peptides from synovium and cartilage, different from that bound by normal serum Ig. One type of intracellular protein detected specifically in RA joints (histones H2A/B) was validated by immunohistology and found to be deposited on the cartilage surface of RA but not OA joints. Thus, autoantibodies to many determinants (whether deposited as ''neoantigens'' or normal constituents of the extracellular matrix) have the potential to contribute to arthritic inflammation.autoantibodies ͉ histones ͉ mass spectrometry ͉ proteomics

show abstract

Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy

Cited by 100 publications

References 24 publications

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis

Contact Info

Product

Resources

About